Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefepime + sulbactam
- Development stage
- Unknown
- Lead developer
- Venus Remedies
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
Cefepime + sulbactam is a fixed-dose combination antibiotic consisting of cefepime, a fourth-generation cephalosporin, and sulbactam, a beta-lactamase inhibitor. Cefepime exerts its bactericidal activity by binding to and inhibiting penicillin-binding proteins (PBPs), which are essential for the synthesis of the bacterial cell wall. Sulbactam acts as a suicide inhibitor of certain beta-lactamases (primarily Class A and some Class C enzymes), thereby protecting cefepime from enzymatic degradation and extending its spectrum of activity against resistant Gram-negative pathogens, including *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. This combination is typically administered parenterally for the treatment of serious systemic infections, particularly those suspected to be caused by multi-drug resistant (MDR) bacteria producing beta-lactamases.
- Brand names
- SupimeCefepime-SCefepime Sulbactam
- Other names
- cefepime/sulbactamsulbactam + cefepime
02
Targets
Neuraminidaseβ-lactamasePBP1A (Penicillin-binding protein 1A)PBP1b (Penicillin-binding protein 1B)PBP2 (Penicillin-binding protein 2)
Beyond the preview
Go deeper on cefepime + sulbactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefepime + sulbactam.